
Application Serial No.: 10/807,837

Response and Amendment dated: October 9, 2007 Response to Office Action dated May 7, 2007

## In the Claims

1.-14. (Canceled)



15. (Currently amended) An antibody or antibody fragment that binds to a polypeptide comprising a sequence of amino acid residues as shown in SEQ ID NO:3; and

reduces <u>or neutralizes</u> the <del>pro-inflammatory</del> activity of either IL-20 (SEQ ID NO:8) or IL-22 (SEQ ID NO:6).

- (Original) The antibody or antibody fragment according to claim 15, wherein the antibody or antibody fragment reduces the pro-inflammatory activity of both IL-20 (SEQ ID NO:8) and IL-22 (SEQ ID NO:6).
- 17. (Previously presented) The antibody or antibody fragment according to claim 15, wherein the antibody or antibody fragment is (a) a polyclonal antibody, (b) a murine monoclonal antibody, (c) a humanized antibody derived from (b), (d) an antibody fragment, or (e) a human monoclonal antibody.
- 18. (Original) The antibody or antibody fragment according to claim 15, wherein the antibody further comprises a radionuclide, enzyme, substrate, cofactor, fluorescent marker, chemiluminescent marker, peptide tag, magnetic particle, drug, or toxin.
- 19. (Original) The antibody of claim 17, wherein the antibody further comprises PEGylation.
- 20. (Previously presented) The antibody or antibody fragment according to claim 16, wherein the antibody or antibody fragment is (a) a polyclonal antibody, (b) a murine monoclonal antibody, (c) a humanized antibody derived from (b), (d) an antibody fragment, or (e) a human monoclonal antibody.

Application Serial No.: 10/807,837

Response and Amendment dated: October 9, 2007 Response to Office Action dated May 7, 2007

- 21. (Original) The antibody or antibody fragment according to claim 16, wherein the antibody further comprises a radionuclide, enzyme, substrate, cofactor, fluorescent marker, chemiluminescent marker, peptide tag, magnetic particle, drug, or toxin.
- 22. (Original) The antibody of claim 20, wherein the antibody further comprises PEGylation.

## 23. – 54. (Canceled)

- 55. (Currently amended) An antibody comprising a monoclonal antibody that specifically binds to an antigenic epitope of human IL-22RA (SEQ ID NO:3) selected from the group consisting of:
  - (a) an epitope consisting of the amino acid sequence of SEQ ID NO:3 from amino acid number 1 (Pro), to amino acid number 6 (Asp) of SEQ ID NO:3;
  - (b) an epitope consisting of the amino acid sequence of SEQ ID NO:3 from amino acid number 26 (Ser), to amino acid number 32 (Pro);
  - (e) an epitope consisting of the amino acid sequence of SEQ-ID-NO:3 from amino acid number 41 (Lys); to amino acid number 47 (Asp);
  - (d) an epitope consisting of the amino acid sequence of SEQ ID NO:2 from amino acid number 49 (Val), to amino acid number 62 (Cys);
  - (e) an epitope consisting of the amino acid-sequence of SEQ ID NO:3 from amino acid number 41 (Lys) to amino acid number 62 (Cys);
  - (f)—an epitope consisting of the amino acid sequence of SEQ ID NO:3 from amino acid number 84 (Ala) to amino acid number 97 (Ser);
  - (g) an epitope consisting of the amino acid-sequence of SEQ ID NO:3 from amino acid number 103 (Thr) to amino acid number 108 (Asp);
  - (h) an opitope consisting of the amino acid sequence of SEQ ID NO:3 from amino acid number 130 (Arg) to amino acid number 135 (His);
  - (i) an epitope consisting of the amino acid sequence of SEQ ID NO:3 from amino acid number 164 (Gly) to amino acid number 166 (Lys);

Application Serial No.: 10/807,837

Response and Amendment dated: October 9, 2007 Response to Office Action dated May 7, 2007

- (j) an epitope consisting of the amino acid sequence of SEQ ID NO:3 from amino acid number 175 (Tyr), to amino acid number 179 (Glu);
- (k) an epitope consisting of the amino acid sequence of SEQ ID-NO:3-from amino acid number 193 (Lys) to amino acid number 196 (Ala);
- (1)—an epitope consisting of the amino acid sequence of SEQ ID NO:3 from amino acid number 203 (Lys) to amino acid number 209 (Thr); and
- (m) an epitope consisting of the amino acid sequence of SEQ ID NO:3; and
- (n) an epitope consisting of the amino acid sequence of SEQ ID NO:4; and wherein the antibody reduces or neutralizes the activity of either human IL-22 (SEQ ID NO:6) or IL-20 (SEQ ID NO:8).
- 56. (Original) The antibody of claim 55, wherein the antibody reduces or neutralizes the activity of both human IL-22 (SEQ ID NO:6) and IL-20 (SEQ ID NO:8).
- 57. (Original) The antibody of claim 55, wherein the antibody is selected from the group consisting of: (a) a murine monoclonal antibody, (b) a humanized antibody derived from (a), (c) an antibody fragment, and (d) a human monoclonal antibody.
- 58. (Original) The antibody of claim 57, wherein the antibody further comprises PEGylation.
- 59. (Original) The antibody of claim 56, wherein the antibody is selected from the group consisting of: (a) a murine monoclonal antibody, (b) a humanized antibody derived from (a), (c) an antibody fragment, and (d) a human monoclonal antibody.
- 60. (Original) The antibody of claim 59, wherein the antibody further comprises PEGylation.

## 61.-73. (Canceled)